Science Translational Medicine
07 July 2021 Vol 13, Issue 60
Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
By Heather Kalish, Carleen Klumpp-Thomas, Sally Hunsberger, Holly Ann Baus, Michael P. Fay, Nalyn Siripong, Jing Wang, Jennifer Hicks, Jennifer Mehalko, Jameson Travers, Matthew Drew, Kyle Pauly, Jacquelyn Spathies, Tran Ngo, Kenneth M. Adusei, Maria Karkanitsa, Jennifer A. Croker, Yan Li, Barry I. Graubard, Lindsay Czajkowski, Olivia Belliveau, Cheryl Chairez, Kelly R. Snead, Peter Frank, Anandakumar Shunmugavel, Alison Han, Luca T. Giurgea, Luz Angela Rosas, Rachel Bean, Rani Athota, Adriana Cervantes-Medina, Monica Gouzoulis, Brittany Heffelfinger, Shannon Valenti, Rocco Caldararo, Michelle M. Kolberg, Andrew Kelly, Reid Simon, Saifullah Shafiq, Vanessa Wall, Susan Reed, Eric W. Ford, Ravi Lokwani, John-Paul Denson, Simon Messing, Sam G. Michael, William Gillette, Robert P. Kimberly, Steven E. Reis, Matthew D. Hall, Dominic Esposito, Matthew J. Memoli, Kaitlyn Sadtler
Science Translational Medicine07 Jul 2021 Open Access
16.8 million SARS-CoV-2 infections in the US went undiagnosed in the first 6 months of the pandemic compared to 3.5 million diagnosed infections.
Elucidating seroprevalence in COVID-19
Symptoms of SARS-CoV-2 infection range from completely asymptomatic, to those of a common cold, to a drop in oxygen saturation and lung function, and death in some patients. To evaluate the proportion of the U.S. population who had an undiagnosed infection during the first wave of the COVID-19 pandemic, we measured antibody prevalence in study participants who had not previously been diagnosed with a SARS-CoV-2 infection. By mid-July of 2020, 16.8 million people had an undiagnosed SARS-CoV-2 infection, almost five times the rate of diagnosed infections.